Clinical Trial Detail

NCT ID NCT03976102
Title Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera in LTB Follicular Lymphoma (FLINTER) (FLINTER)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Dr. Reddy's Laboratories Limited
Indications

follicular lymphoma

Therapies

Rituximab

DRL_RI

Age Groups: senior adult

No variant requirements are available.